Introduction KL-6 (Krebs von den Lungen-6) is a high molecular weight mucinous glycoprotein that was discovered as a pulmonary adenocarcinoma-related antigen. A KL-6 monoclonal antibody reacts with the sugar moiety of the mucin MUC-1 [22] . MUC-1 is found in the mucosal epithelium of the respiratory and digestive systems, as well as the epithelial cells of the cornea and conjunctiva [12] . It has been reported that the biochemical properties of KL-6 are similar to those of other MUC-1 mucins [10] . In normal lung tissue, KL-6 appears on type II pneumonocytes, respiratory bronchiolar epithelial cells, and bronchial gland cells [22] . Currently, it is classified as Cluster 9 antigen (MUC-1) under the pulmonary cell antigen cluster classification proposed at the Third International Workshop on Lung Tumor and Differentiation Antigens [30] .
Measurement of serum KL-6 levels is now widely accepted in Japan as a diagnostic examination to monitor the activity of lung diseases, such as idiopathic interstitial pneumonia [20, 21] , radiation pneumonia [5] , pneumonia following bone marrow transplantation [1] , Pneumocystis carinii pneumonia in the immunocompromised host [6] , pediatric respiratory diseases [11, 26] , breast cancer [29] , Amiodarone-induced pulmonary toxicity [3] , Mycoplasma pneumonia [27] , interstitial pneumonia associated with collagen diseases [25] , and pulmonary sarcoidosis [21] , Additionally, we recently demonstrated that serum KL-6 levels are elevated in uveitic patients with sarcoidosis [19] . Although there are only a few reports describing the influences of ocular disorders on serum KL-6 level, it was lately reported that impression cytology indicated higher KL-6 expression in the ocular surface epithelium of the patients with dry eye than in healthy subjects [7] .
Uveitis in patients with systemic sarcoidosis is common in any race, gender, or age, and sarcoidosis is also an immunological and systemic disease involving almost all organs in the body [34] . It is one of the most frequently diagnosed diseases in patients with endogenous uveitis worldwide [8, 15, 23, 33] . Now it is known that angiotensin-converting enzyme (ACE) is a helpful serum marker for the diagnosis of sarcoidosis. ACE is thought to be one of the most useful markers to diagnose sarcoidosis; however, while specific, it is not very sensitive. Another problem of ACE is that ACE inhibitory agents may be administrated into some patients with blood hypertension because it is one of the general antihypertensive drugs. When hypertension is treated with ACE inhibitors, their serum ACE levels should markedly decrease. In addition, ACE levels fluctuate with corticosteroid use [31] . Thus, clinically it is important to find another helpful laboratory parameter to diagnose sarcoidosis and/or to monitor the severity of the disease.
Sarcoidosis is a Th1-mediated disease, and recent reports have identified some immunological markers possibly indicating sarcoidosis: up-regulated intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecules-1 (VCAM-1) on macrophages, and/or the presence of inducible NO synthase (iNOS) in bronchoalveolar lavage fluid (BALF) [32] . We previously detected high levels of serum macrophage migration inhibitory factor (MIF) in the uveitis patients with sarcoidosis [18, 24] .
In the present study, we quantified serum KL-6 levels in patients with sarcoidosis, and evaluated their usefulness in monitoring the disease severity.
Materials and methods

Patients
After obtaining informed consent in accordance with the tenets of the Declaration of Helsinki, sera were obtained from 40 uveitis patients with sarcoidosis at the Uveitis Survey Clinic of the Hokkaido University Hospital, Sapporo, Japan. The mean age was 49.3 years old (25-68 years old), and 31 of 40 cases were women. Three of them were treated with systemic corticosteroid, and an anti-hypertensive drug was given to another subject systemically. The criteria established by the Diffuse Pulmonary Disease Research Committee of Japan were used to diagnose patients with sarcoidosis [9] .
Measurement of KL-6
Human KL-6 levels were determined with a PICOLUMI KL-6 kit (Eisai, Tokyo, Japan), an electrochemiluminescence immunoassay (ECLIA) specific for human KL-6, containing all the necessary reagents for the assay. Beads bound with anti-KL-6 mouse monoclonal antibodies (Eisai) were prepared as a solid phase and placed into a 96-well plate.
Venous blood samples were collected in sterile vacuum tubes and centrifuged for 30 min at the Hokkaido University Hospital, as described previously [16] [17] [18] . The serum samples were diluted one in 50 and 20 μl was mixed with 25 μl of anti-KL-6 coated beads; the mixture was incubated for 9 min at 30°C. The beads were washed, mixed, and incubated for 9 min with ruthenium (Ru)-labeled anti-KL-6 monoclonal antibody, which illuminates in response to electrochemical stimuli. An electric impulse was applied via an electrode using a PICOLUMI8220 automated immunoassay reader (Sanko Junyaku, Tokyo, Japan), followed by washing the beads. The level of luminescence for the Ru complexes bound to solid-phase antibodies reflects the amount of KL-6 in the sample. The concentration of KL-6 in the serum sample was calculated by comparing the sample's luminescence with those of calibrated solutions of known KL-6 standards. 
Results
Serum KL-6 and ACE levels in patients with sarcoidosis
The mean KL-6 concentrations in the sera of 36 sarcoidosis patients and sex/age-matched healthy volunteers were 449.3±66.3 (standard error) and 192.1±11.3 (U/ml), respectively. The average level of KL-6 in the sera of sarcoidosis patients was significantly higher (P<0.001) than that of healthy control subjects (Fig. 1) .
To determine whether serum KL-6 levels are associated with serum ACE levels, we plotted the two values in the patients with sarcoidosis. We previously reported that although both serum ACE and KL-6 levels were significantly higher than in controls, these two values were not correlated among all uveitic patients, including sarcoidosis, Behçet's disease, Vogt-Koyanagi-Harada's disease, and HLA-B27 associated uveitis, unclassified uveitis, and healthy subjects [19] . In the present study, we picked up and plotted KL-6 and ACE values in the patients with sarcoidosis (Fig. 2) . Four of 40 sarcoidosis patients were excluded because they were given corticosteroid and antihypertensive agents. Significant correlation was detected between the serum levels of KL-6 and those of ACE in sarcoidosis (correlation coefficient was 0.70, t=5.715, df= 34, and P<0.0001).
We then examined three patients with sarcoidosis before and after starting their systemic corticosteroid administrations. Their serum ACE and KL-6 levels were quantified before and 6-15 months after the initiation of corticosteroid administration (10 or 20 mg of predonisolone) (Fig. 3) . Since serum ACE level is considered susceptible to corticosteroid administration, it is reasonable that their serum ACE levels decrease after treatment. In contrast, KL-6 levels were little influenced by systemic corticosteroid treatment in two of three tested patients (Fig. 3) .
Next, we found a case with sarcoidosis complicated with blood hypertension, and serially reviewed her serum KL-6 and ACE levels (Fig. 4) . The patient was a 68-year-old woman, and she had already been treated with ACE inhibitory drug (5 mg/day of imidaprilhydrochloride) when she visited our clinic at the first time. Her serum ACE levels were quite low (1.9 IU/l) at the first examination. Thereafter, her serum ACE levels once markedly increased (14.0 IU/l) due to change from the ACE inhibitor to valsartan (40 mg/day), a specific angiotensin subtype 1 (AT1) receptor blocker. After a year, her ACE level decreased again (1.3 IU/l) because her primary care physician began a combined medication consisting of the ACE inhibitor and the AT1 blocker. However, her serum KL-6 level was not influenced by imidaprilhydrochloride or valsartan (Fig. 4) . Fig. 3 Serial observation of serum KL-6 and ACE levels. Three sarcoidosis patients were treated with systemic corticosteroid. Each line shows individual subjects. Serum KL-6 levels (top) were less affected by systemic corticosteroid administration than ACE (bottom) Fig. 2 Plots of serum KL-6 and ACE levels in uveitis patients with sarcoidosis. Each circle shows individual subjects. Significant correlation was found between the serum levels of KL-6 and those of ACE in 36 patients with sarcoidosis (correlation coefficient was 0.70) Discussion KL-6 is a member of the MUC-1 family of mucins and is recognized by a mouse monoclonal antibody against a sialylated carbohydrate chain [22] . The anti-KL-6 monoclonal antibody reacts with an antigen strongly expressed on type II alveolar pneumonocytes and bronchiolar epithelial cells, but not on granulomatous tissue [22] . At present, quantification of the serum KL-6 level is considered useful to diagnose and examine the severity of interstitial pneumonia in Japan. However, its usefulness for ocular disorders has remained unclear. Though it is accepted that MUC-1 is expressed in normal human conjunctiva and cornea [2, 7, 12] , the expression of MUC-1/KL-6 in other ocular tissues had been unknown. Recently, we and others have reported that determination of the serum KL-6 levels is quite useful for both pulumonologists and ophthalmologists to care for patients with sarcoidosis [21, 23] . Since some sarcoidosis patients suffer from damage to alveolar cells in the lung, it is reasonable to suggest that the elevated serum levels of KL-6 in sarcoidosis are due to its production or release by alveolar pneumonocytes and bronchiolar epithelial cells. However, it had remained unclear whether pulmonary tissues are the only sources of elevated serum KL-6 in uveitic patients with sarcoidosis. In the present study, we did not detect the KL-6 expression in the uvea (iris, ciliary body, and choroid), but did so in the cornea/ conjunctiva (data not shown). However, the volume of ocular tissue is much smaller than lung. These results suggest that the systemic elevation of serum KL-6 levels mainly depends upon the destruction of pulmonary tissues. Other possible sources of KL-6 in the inflamed eyes may be corneal and conjunctival cells. Though their contribution rates to raising of the systemic level of KL-6 might be small, sarcoid granulomas are seen in 7-17% of sarcoidosis patients with ocular involvement [13, 14, 28] , suggesting that sarcoidosis frequently invades into the ocular surface. Thus, it is possible that inflamed eye with sarcoidosis is one of the possible candidate organs to raise KL-6 level.
Though clinicians already use serum ACE level as a laboratory marker for sarcoidosis, ACE measurement identifies only 50-67% of uveitis patients with sarcoidosis at our clinic [4, 19] . As it is thought that the granulomatous tissue can release ACE, serum ACE levels may be elevated in other granulomatous conditions such as tuberculosis, lymphoma, and asbestosis. Furthermore, some patients who are suffering from hypertension and/or heart failure may be treated with ACE inhibitors, a kind of anti-hypertensive drug. Since we have demonstrated in the present study that serum KL-6 levels are unaffected by ACE-inhibitory drugs, different from serum ACE levels, and less affected by corticosteroid than by ACE, it may be worthwhile to add measurement of serum KL-6 levels to the procedures to manage sarcoidosis. It is also possible that ACE measurement may be substituted by serum KL-6 levels for sarcoidosis patients when serum ACE values are unreliable for other reason.
Today, histological examinations of lung, conjunctiva, or lacrimal gland biopsy specimens are also accepted for diagnosing sarcoidosis. However, in the respect that biopsy sometimes causes much discomfort and pain to the patients, to add another laboratory parameter, KL-6, may provide a less invasive and a less expense laboratory test to screen and monitor sarcoidosis. Despite the fact that it remains unclear how much KL-6 should be released from ocular tissue in the patients with sarcoidosis, we would like to emphasize that KL-6 is considered a new and useful laboratory parameter for the diagnosis and management of uveitis patients with sarcoidosis, even when the patients are treated with systemic corticosteroid and/or anti-hypertensive drugs. Fig. 4 Serial observation of serum KL-6 and ACE levels. A case of sarcoidosis was given ACE inhibitory drug, an anti-hypertensive agent, at her first visit to our clinic. When her medication was changed to AT1 blocker, another type of anti-hypertensive drug, her ACE level increased. Subsequently, her hypertension was treated with combination of ACE inhibitor and AT1 blocker; her ACE level then decreased again. However, neither ACE inhibitor nor AT1 blocker affected serum KL-6 levels
